Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants |
| |
Authors: | P. E. Wallemacq Raymond Reding Etienne M. Sokal Jean Ville de Goyet Stéphane Clement de Clety Véronique Van Leeuw Marc De Backer Jean-Bernard Otte |
| |
Affiliation: | (1) Department of Clinical Chemistry, Saint Luc University Hospital, Avenue Hippocrate 10, B-1200 Brussels, Belgium Fax: +32 2 764 3732, BE;(2) Department of Pediatric Surgery, Saint Luc University Hospital, Avenue Hippocrate 10, B-1200 Brussels, Belgium, BE;(3) Department of Emergency Medicine and Intensive Care, Saint Luc University Hospital, Avenue Hippocrate 10, B-1200 Brussels, Belgium, BE;(4) Sandoz Pharma Division, B-1030 Brussels, Belgium, BE |
| |
Abstract: | Pediatric liver transplant recipients constitute a population characterized by a particularly unpredictable and poor bioavailability of cyclosporin (CyA). Even though several adult studies show that the new oral formulation of CyA, Neoral (NEO), produces better bioavailability and blood level predictability, few data describe its pharmacokinetics in children. We performed a complete analysis of the pharmacokinetics of NEO in ten small children after primary liver transplantation. Three pharmacokinetic profiles were set up with data obtained from tests taken during i. v. administration of CyA, after the first oral NEO dose, and after the last NEO dose before discharge from the hospital. The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22 % and 21 % for the first and last NEO doses. A large interpatient variability was observed. This was due, in part, to episodes of diarrhea that interfered with the pharmacokinetic evaluation and, in part, to the variability of post-transplant hepatic function. There was a good correlation between CyA trough levels and their related AUCs for both NEO profiles (r = 0.93 and r = 0.74, respectively). We conclude that, even though the pediatric OLT population remains more unpredictable than that of adults, NEO has a relatively rapid half-life and a remarkably improved bioavailability. Received: 29 November 1996 Received after revision: 10 April 1997 Accepted: 15 May 1997 |
| |
Keywords: | Pediatric liver transplantation Neoral pharmacokinetics Liver transplantation pediatric Neoral Neoral liver transplantation pediatric Pharmacokinetics Neoral pediatric liver transplantation |
本文献已被 SpringerLink 等数据库收录! |
|